Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$10.74
+1.5%
$10.06
$9.22
$14.63
$1.29B1.032.15 million shs1.33 million shs
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$0.00
$0.00
$1.59
$1K1.535.40 million shsN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$21.43
-2.4%
$18.37
$2.03
$14.36
$201.40M1.1150,104 shs113,400 shs
Organigram Global Inc. stock logo
OGI
Organigram Global
$1.48
+2.1%
$1.34
$0.85
$2.08
$198.23M1.36665,791 shs550,860 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.49
+4.4%
$3.50
$2.28
$6.71
$569.56M1.71.14 million shs678,167 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
+1.51%+4.27%+4.58%-5.87%-0.09%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00%0.00%0.00%0.00%-99.99%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00%+6.67%+8.45%+96.79%-49.67%
Organigram Global Inc. stock logo
OGI
Organigram Global
+2.07%+6.47%+5.71%+42.31%-12.68%
Organogenesis stock logo
ORGO
Organogenesis
+4.42%+5.65%+46.25%+3.94%+54.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
4.3727 of 5 stars
3.32.00.04.72.11.71.9
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
1.1611 of 5 stars
0.01.00.00.03.10.02.5
Organogenesis stock logo
ORGO
Organogenesis
4.4141 of 5 stars
3.03.00.04.32.54.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.50
Moderate Buy$24.00123.46% Upside
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00
N/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
3.00
BuyN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$6.0033.63% Upside

Current Analyst Ratings Breakdown

Latest DVAX, MTEM, OGI, ORGO, and NLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.00
4/17/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$12.00 ➝ $10.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$294.62M4.38$0.16 per share66.81$4.54 per share2.37
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$23.48M0.00N/AN/A$0.78 per share0.00
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
$117.47M1.69N/AN/A$2.07 per share0.71
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.18$0.22 per share20.61$2.09 per share2.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$27.31M-$0.52N/A21.92N/A-20.39%3.59%2.20%8/5/2025 (Estimated)
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A
Organigram Global Inc. stock logo
OGI
Organigram Global
-$33.39M$0.1014.80N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)

Latest DVAX, MTEM, OGI, ORGO, and NLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q3 2025
Organigram Global Inc. stock logo
OGI
Organigram Global
-$0.01N/AN/AN/A$68.04 millionN/A
8/5/2025Q2 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.12N/AN/AN/A$87.55 millionN/A
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/6/2025Q1 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.49
11.93
10.84
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/A
1.56
1.56
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33
Organigram Global Inc. stock logo
OGI
Organigram Global
N/A
3.42
1.90
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67

Institutional Ownership

CompanyInstitutional Ownership
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
96.96%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
95.47%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%
Organigram Global Inc. stock logo
OGI
Organigram Global
34.63%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
350120.08 million116.50 millionOptionable
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
2606.58 million5.67 millionNo Data
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data
Organigram Global Inc. stock logo
OGI
Organigram Global
860133.94 million133.82 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable

Recent News About These Companies

Organogenesis Holdings Inc. (ORGO) - Yahoo Finance
CMS reviewing coverage policies for skin substitute products

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

$10.74 +0.16 (+1.51%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$10.74 -0.01 (-0.05%)
As of 07/14/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Molecular Templates stock logo

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$21.43 -0.53 (-2.41%)
As of 07/11/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Organigram Global stock logo

Organigram Global NASDAQ:OGI

$1.48 +0.03 (+2.07%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$1.46 -0.02 (-1.35%)
As of 07/14/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.49 +0.19 (+4.42%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$3.16 -1.34 (-29.73%)
As of 07/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.